CHENGDU, China, Sept. 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new drug application (NDA) for the Company's small molecule rearranged during transfection (RET) kinase inhibitor A400 (also known as EP0031) was accepted for...
Hence then, the article about kelun biotech s new drug application for its novel next generation selective ret inhibitor a400 ep0031 accepted for review by the nmpa for the treatment of ret fusion positive nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Kelun-Biotech's New Drug Application for Its Novel Next-generation Selective RET Inhibitor A400/EP0031 Accepted for Review by the NMPA for the Treatment of RET-fusion positive NSCLC )
Also on site :
- Zara Larsson Talks Macklemore Speaking Out, Her Workout Routine & Viral Concert Moments .. Billboard News Interview
- Paranormal Comedy ‘Don’t F — k With Ghosts’ Premieres On Demand, Launches Original YouTube Channel (EXCLUSIVE)
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NuScale Power Corporation - SMR